Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823860 | 0.88 | CES2 (0.39) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL823838 | 0.81 | CES2 (0.41) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL30917919 | 0.80 | CES2 (0.42) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL30334733 | 0.78 | CES2 (0.35) | CES2HDAC4HDAC1HDAC6 | |
| SCHEMBL823713 | 0.77 | CES2 (0.40) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL823819 | 0.76 | CES2 (0.34) | CES2HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL1471178 | 0.76 | ALDH1A1 (0.38) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL29518865 | 0.76 | MEN1 (0.52) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1469721 | 0.76 | MEN1 (0.52) | CES2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL29518923 | 0.76 | ALDH1A1 (0.38) | CES2HDAC4HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142720-B2 | Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules | IMEC (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | IMEC (BE) | 2010-11-11 | — | — | US | disclosed |
| US-7770437-B2 | Thiol or disulfide molecules having poly(ethylene oxide) groups for use in a self assembled monolayer bound to a metal layer for covalently immobilizing biomolecules in a biosensor | IMEC (BE) | 2010-08-10 | — | — | US | disclosed |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | IMEC (BE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | EBPL, SPR, MB | CES2 2139/4885HDAC4 3620/4885HDAC1 3962/4885 |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | EBPL, AEBP2, NAPA | CES2 920/4885HDAC4 4109/4885HDAC1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.